These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20337580)

  • 1. Recent advances in the design of cathepsin S inhibitors.
    Wiener JJ; Sun S; Thurmond RL
    Curr Top Med Chem; 2010; 10(7):717-32. PubMed ID: 20337580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonpeptidic, noncovalent inhibitors of the cysteine protease cathepsin S.
    Thurmond RL; Beavers MP; Cai H; Meduna SP; Gustin DJ; Sun S; Almond HJ; Karlsson L; Edwards JP
    J Med Chem; 2004 Sep; 47(20):4799-801. PubMed ID: 15369380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 2: Optimization of P1 and N-aryl.
    Alper PB; Liu H; Chatterjee AK; Nguyen KT; Tully DC; Tumanut C; Li J; Harris JL; Tuntland T; Chang J; Gordon P; Hollenbeck T; Karanewsky DS
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1486-90. PubMed ID: 16412634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Major histocompatibility complex class II-associated p41 invariant chain fragment is a strong inhibitor of lysosomal cathepsin L.
    Bevec T; Stoka V; Pungercic G; Dolenc I; Turk V
    J Exp Med; 1996 Apr; 183(4):1331-8. PubMed ID: 8666891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of selective and nonpeptidic cathepsin S inhibitors.
    Irie O; Ehara T; Iwasaki A; Yokokawa F; Sakaki J; Hirao H; Kanazawa T; Teno N; Horiuchi M; Umemura I; Gunji H; Masuya K; Hitomi Y; Iwasaki G; Nonomura K; Tanabe K; Fukaya H; Kosaka T; Snell CR; Hallett A
    Bioorg Med Chem Lett; 2008 Jul; 18(14):3959-62. PubMed ID: 18572405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cathepsin S inhibitors as novel immunomodulators.
    Thurmond RL; Sun S; Karlsson L; Edwards JP
    Curr Opin Investig Drugs; 2005 May; 6(5):473-82. PubMed ID: 15912960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The design of potent hydrazones and disulfides as cathepsin S inhibitors.
    Cywin CL; Firestone RA; McNeil DW; Grygon CA; Crane KM; White DM; Kinkade PR; Hopkins JL; Davidson W; Labadia ME; Wildeson J; Morelock MM; Peterson JD; Raymond EL; Brown ML; Spero DM
    Bioorg Med Chem; 2003 Mar; 11(5):733-40. PubMed ID: 12538003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L.
    Falgueyret JP; Oballa RM; Okamoto O; Wesolowski G; Aubin Y; Rydzewski RM; Prasit P; Riendeau D; Rodan SB; Percival MD
    J Med Chem; 2001 Jan; 44(1):94-104. PubMed ID: 11141092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-covalent cathepsin K inhibitors for the treatment of osteoporosis.
    Kim TS; Tasker AS
    Curr Top Med Chem; 2006; 6(4):355-60. PubMed ID: 16611147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cathepsin S inhibitors: 2004-2010.
    Lee-Dutra A; Wiener DK; Sun S
    Expert Opin Ther Pat; 2011 Mar; 21(3):311-37. PubMed ID: 21342054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring inhibitor binding at the S' subsites of cathepsin L.
    Chowdhury SF; Joseph L; Kumar S; Tulsidas SR; Bhat S; Ziomek E; Ménard R; Sivaraman J; Purisima EO
    J Med Chem; 2008 Mar; 51(5):1361-8. PubMed ID: 18278855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics.
    Yasuda Y; Kaleta J; Brömme D
    Adv Drug Deliv Rev; 2005 May; 57(7):973-93. PubMed ID: 15876399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in cathepsin S inhibitor design.
    Link JO; Zipfel S
    Curr Opin Drug Discov Devel; 2006 Jul; 9(4):471-82. PubMed ID: 16889230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cathepsins X and B display distinct activity profiles that can be exploited for inhibitor design.
    Ménard R; Therrien C; Lachance P; Sulea T; Qo H; Alvarez-Hernandez AD; Roush WR
    Biol Chem; 2001 May; 382(5):839-45. PubMed ID: 11517939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benzodioxocin-3-ones and N-acyl-3-amino-3-buten-2-ones: novel classes of cathepsin K cysteine protease inhibitors.
    Yamashita DS; Xie R; Lin H; Wang B; Shi SD; Quinn CJ; Hemling ME; Hissong C; Tomaszek TA; Veber DF
    J Pept Res; 2004 Mar; 63(3):265-9. PubMed ID: 15049838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a potent and selective noncovalent cathepsin S inhibitor.
    Thurmond RL; Sun S; Sehon CA; Baker SM; Cai H; Gu Y; Jiang W; Riley JP; Williams KN; Edwards JP; Karlsson L
    J Pharmacol Exp Ther; 2004 Jan; 308(1):268-76. PubMed ID: 14566006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invariant chain processing is independent of cathepsin variation between primary human B cells/dendritic cells and B-lymphoblastoid cells.
    Reich M; Zou F; Sieńczyk M; Oleksyszyn J; Boehm BO; Burster T
    Cell Immunol; 2011; 269(2):96-103. PubMed ID: 21543057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based development of pyridoxal propionate derivatives as specific inhibitors of cathepsin K in vitro and in vivo.
    Katunuma N; Matsui A; Inubushi T; Murata E; Kakegawa H; Ohba Y; Turk D; Turk V; Tada Y; Asao T
    Biochem Biophys Res Commun; 2000 Jan; 267(3):850-4. PubMed ID: 10673380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active Site Mapping of Human Cathepsin F with Dipeptide Nitrile Inhibitors.
    Schmitz J; Furtmann N; Ponert M; Frizler M; Löser R; Bartz U; Bajorath J; Gütschow M
    ChemMedChem; 2015 Aug; 10(8):1365-77. PubMed ID: 26119278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of cathepsin inhibitors and structure-based design of cathepsin B-specific inhibitor.
    Tomoo K
    Curr Top Med Chem; 2010; 10(7):696-707. PubMed ID: 20337581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.